Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report

Overview of attention for article published in Frontiers in Neurology, August 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 10,808 followers.

Neuromyelitis optica spectrum disorder (NMOSD), a multiple sclerosis -like disorder, can be treated with cutting edge monoclonal antibodies. These are usually reserved for prevention, but we describe here use in the acute attack setting. https://t.co/UIdZ

04 Nov 2022

Reply Repost Favourite

New Research: Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report: Introduction Eculizumab has been shown to be an effective and typically well-tolerated medication in the treatment of neuromyelitis optica… https://t.co/A0N

08 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.